These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 23161460)
21. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L; Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034 [TBL] [Abstract][Full Text] [Related]
22. Fingolimod-associated amenorrhea: a report of three cases. Alroughani R Mult Scler; 2014 Oct; 20(12):1662-4. PubMed ID: 24515730 [TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla A; Karkare SU; Balderston McGuiness C; Korn JR Curr Med Res Opin; 2013 Dec; 29(12):1647-56. PubMed ID: 24059944 [TBL] [Abstract][Full Text] [Related]
24. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod. Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493 [No Abstract] [Full Text] [Related]
25. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Jander S; Turowski B; Kieseier BC; Hartung HP Mult Scler; 2012 Nov; 18(11):1650-2. PubMed ID: 23100527 [TBL] [Abstract][Full Text] [Related]
27. [Fingolimod in the treatment of multiple sclerosis. Novelties presented at the annual congress of the American Academy of Neurology (Toronto, April 2010)]. Rabasseda X Drugs Today (Barc); 2010 Jul; 46 Suppl D():1-14. PubMed ID: 20820453 [TBL] [Abstract][Full Text] [Related]
28. Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis. Filippi M Nat Rev Neurol; 2011 Feb; 7(2):74-5. PubMed ID: 21297650 [No Abstract] [Full Text] [Related]
29. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia. Tanaka M; Park K; Tanaka K Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501 [No Abstract] [Full Text] [Related]
31. Fingolimod for multiple sclerosis. Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953 [TBL] [Abstract][Full Text] [Related]
32. Multiple sclerosis reactivation postfingolimod cessation: is it IRIS? Alroughani R; Almulla A; Lamdhade S; Thussu A BMJ Case Rep; 2014 Oct; 2014():. PubMed ID: 25320259 [TBL] [Abstract][Full Text] [Related]
33. Oral fingolimod to treat multiple sclerosis: see your cardiologist first. Sato DK; Callegaro D Arq Neuropsiquiatr; 2014 Sep; 72(9):651-2. PubMed ID: 25252227 [No Abstract] [Full Text] [Related]
34. Novartis eyes oral MS drug as potential blockbuster. Ratner M Nat Biotechnol; 2010 Nov; 28(11):1135-6. PubMed ID: 21057464 [No Abstract] [Full Text] [Related]
35. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Brinkmann V; Billich A; Baumruker T; Heining P; Schmouder R; Francis G; Aradhye S; Burtin P Nat Rev Drug Discov; 2010 Nov; 9(11):883-97. PubMed ID: 21031003 [TBL] [Abstract][Full Text] [Related]
36. Fingolimod for multiple sclerosis: a review for the specialist nurse. Harrison K Br J Nurs; 2014 Jun 12-25; 23(11):582-9. PubMed ID: 24933548 [TBL] [Abstract][Full Text] [Related]
37. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H; Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031 [TBL] [Abstract][Full Text] [Related]
38. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. Gasperini C; Ruggieri S Drug Des Devel Ther; 2012; 6():175-86. PubMed ID: 22888218 [TBL] [Abstract][Full Text] [Related]